Pharmaceuticals
June 27, 2024
Haron Avgana, Roni Shira Toledano, Irit Akirav
8 citations
MDMA-assisted psychotherapy has shown potential as an effective treatment for post-traumatic stress disorder (PTSD). Preclinical studies involving rodents have demonstrated that MDMA can facilitate the extinction of fear memories. It has been noted that MDMA impacts oxytocin neurons and pro-inflammatory cytokines. Thus, the aim of this study was to explore the role of oxytocinergic signaling...
Mental Health Weekly
June 14, 2024
Valerie A. Canady
A recent decision by the U.S. Food and Drug Administration's (FDA) advisory committee to reject psychedelic treatment and therapy to treat post‐traumatic stress disorder (PTSD), citing that the available evidence of midomafetamine, better known as MDMA, fails to show that the drug is effective, has been met with mixed reaction by a member of the field and an advocacy organization committed to...
Alcoholism & Drug Abuse Weekly
June 10, 2024
Alison Knopf
Last week, the Food and Drug Administration (FDA) voted 9‐2 to reject the application of Lykos Therapeutics, the newly formed commercial arm of MAPS, for “midomafetamine” (actually MDMA, or methylenedioxymethamphetamine) to treat post‐traumatic stress disorder (PTSD).
Journal of Student Research
May 31, 2024
Mia Panin, Jason Abercrombie
Post-traumatic stress disorder (PTSD) is an often debilitating condition caused by a person’s exposure to traumatic events. Symptoms of PTSD include intrusive thoughts, suicidal ideation, and highly negative and distressing emotional states. Current treatments for PTSD such as cognitive behavioral therapy, EMDR, and SSRIs and SNRIs are ineffective for a large chunk of patients who seek out...
The British Journal of Psychiatry
May 20, 2024
David Nutt, Ilana B Crome, Allan H. Young
18 citations
Australia has just rescheduled two drugs controlled under the United Nations Psychotropic Drug Conventions, psilocybin and MDMA, as treatments for treatment-resistant depression and post-traumatic stress disorder respectively. This feature explores the reasons for these developments, the opportunities and challenges they provide to psychiatry communities and how along with health systems these...
Læknablaðið
May 1, 2024
Helga Thorarinsdottir, Berglind Gudmundsdottir, Engilbert Sigurðsson
1 citation
MDMA is a potential novel treatment for post-traumatic stress disorder (PTSD). Our goal is to review current knowledge on MDMA and its use in MDMA-assisted psychotherapy for PTSD. Literature searches were done on PubMed, Web of Science and Google Scholar and references reviewed in identified articles. MDMA-assisted therapy for PTSD usually consists of a few preparatory sessions before two or...
Brain Sciences
March 3, 2024
Mario Renato Velit-Salazar, Eloise Cherian, Paulo R Shiroma
13 citations
Objective: This study aims to provide an overview of pharmacological trials that examine the neurocognitive effects of psychedelics among healthy individuals and patients with post-traumatic stress disorder (PTSD) or major depressive disorder (MDD). Methods: The Preferred Reporting Items for Systematic Reviews (PRISMA) was used as a guide to structure and report the findings for this review. A...
Frontiers in Neuroscience
February 7, 2024
Jennifer Warner-Schmidt, Martin Stogniew, Blake Mandell et al.
6 citations
BackgroundPost-traumatic stress disorder (PTSD) is a highly prevalent psychiatric disorder that can become chronic and debilitating when left untreated. Available pharmacotherapies are limited, take weeks to show modest benefit and remain ineffective for up to 40% of patients. Methylone is currently in clinical development for the treatment of PTSD. Preclinical studies show rapid, robust and...
Progress in Neuro-Psychopharmacology and Biological Psychiatry
January 10, 2024
Mesud Sarmanlu, Kim P. C. Kuypers, Patrick Vizeli et al.
17 citations
The application of MDMA in conjunction with psychotherapy has in recent years seen a resurgence of clinical, scientific, and public interest in the treatment of posttraumatic stress disorder (PTSD). Clinical trials have shown promising safety and efficacy, but the mechanisms underlying this treatment form remain largely unestablished. This article explores recent preclinical and clinical...
PLoS One
January 10, 2024
Rachel Yehuda, Leah Bedrosian, Charlotte Harrison et al.
52 citations
Introduction There is a resurgence of interest in the therapeutic potential of psychedelic substances such as 3,4-methylenedioxymethamphetamine (MDMA). Primary findings from our randomized, double-blind, placebo-controlled, multi-site Phase 3 clinical trial of participants with severe PTSD (NCT03537014) showed that MDMA-assisted therapy induced significant attenuation in the...